Full Text of PDF (467k)
Article in Japanese
Abstract
Case Report
Antitumor activity of alectinib against central nervous system metastases in patients with crizotinib-resistant ALK-positive lung cancer
Keigo Kobayashia Nasa Morokawaa Kyoko Murasea Shigeo Hanadaa Hisashi Takayaa Kazuma Kishia,b
aDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital
bOkinaka Memorial Institute for Medical Research
ABSTRACT
Although crizotinib shows marked and durable activity in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), the central nervous system (CNS) is a frequent site of disease progression in such patients. Alectinib, one of the second-generation ALK inhibitors, is a novel, highly potent, and selective ALK inhibitor that has demonstrated promising antitumor activity in CNS metastases. In this report, we present a series of four ALK-positive NSCLC patients who developed metastatic lesions in CNS, such as brain, leptomeninges, and spinal cord, during crizotinib treatment. All patients subsequently received alectinib, resulting in clinical response without serious side effects. Alectinib was effective for the treatment of CNS metastases in crizotinib-resistant ALK-positive NSCLC patients.
KEYWORDS
ALK-rearranged non-small cell lung cancer Spinal cord metastasis Meningeal carcinomatosis Crizotinib Alectinib
Received 29 Sep 2015 ／ Accepted 2 Mar 2016
AJRS, 5(4): 184-188, 2016
Copyright © The Japanese Respiratory Society All Rights Reserved.